They have developed evidence that TGF-b inhibition of normal intestinal epithelial cell proliferation through the down regulation of an important proto-oncogene, cyclin D1. The central hypotheses for this project are 1) that the TGF-b ligands and their signaling receptors function as important normal constraints on intestinal growth; 2) loss of TGF-b tumor suppressor function is an important early step in the development of dysplastic lesions and cancers of the intestine, and 3) over expression of cyclin D1 may be a mechanism by which tumor cells escape the growth-inhibitory actions of TGF-b. The long term goal of this project is to develop novel targets for therapeutic intervention within these pathways that will beneficial in the treatment and/or prevention of colorectal cancer. This application will be focused on testing the hypotheses through the following specific aims:
Aim 1) To determine the role of the TGF-b Type II Receptor (TbIIR) in rodent models of intestinal hyperplasia and neoplasia. a) The expression of TbIIR and its association with cyclin D1 and K-ras mutation will be examined in Multiple Intestinal Neoplasia (Min) mice and in colonic lesions in azoxymethane treated mice and rats. b) Intestinal carcinogenesis will be examined in mice that express a cominate negative form of the TbIIR in the intestine. C) Crossbreeding of Min mice with transgenic mice that express the dominant negative mutant TbIIR.
Aim 2) To determine whether over expression of cyclin D1 in the mouse intestine results in hyperplasia and neoplasia.
Aim 3) Examine freshly-obtained surgical specimens to determine whether the abnormalities in TbIIR and down stream effectors observed in experimental rodent models are found in human colorectal polyps and cancers. Human colorectal polyps and cancers will be examined to determine whether there is a correlation between cyclin D1 expression, K-ras mutation, and down regulation of the TbIIR. These studies will provide validation for the rodent and cell culture experimental models that will be used to test novel therapeutic interventions aimed at correcting the lesions detected by this project.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK052334-04
Application #
6177882
Study Section
Surgery and Bioengineering Study Section (SB)
Program Officer
May, Michael K
Project Start
1997-06-01
Project End
2002-05-31
Budget Start
2000-06-01
Budget End
2001-05-31
Support Year
4
Fiscal Year
2000
Total Cost
$229,050
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Surgery
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Zhu, Jing; Wang, Jing; Shi, Zhiao et al. (2013) Deciphering genomic alterations in colorectal cancer through transcriptional subtype-based network analysis. PLoS One 8:e79282
Al-Greene, Nicole T; Means, Anna L; Lu, Pengcheng et al. (2013) Four jointed box 1 promotes angiogenesis and is associated with poor patient survival in colorectal carcinoma. PLoS One 8:e69660
Freeman, Tanner J; Smith, J Joshua; Chen, Xi et al. (2012) Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of ?-catenin. Gastroenterology 142:562-571.e2
Shi, Mingguang; Beauchamp, R Daniel; Zhang, Bing (2012) A network-based gene expression signature informs prognosis and treatment for colorectal cancer patients. PLoS One 7:e41292
Hanson, Alison J; Wallace, Heather A; Freeman, Tanner J et al. (2012) XIAP monoubiquitylates Groucho/TLE to promote canonical Wnt signaling. Mol Cell 45:619-28
Singh, Amar B; Sharma, Ashok; Smith, J Joshua et al. (2011) Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer cells. Gastroenterology 141:2140-53
Rachakonda, G; Sekhar, K R; Jowhar, D et al. (2010) Increased cell migration and plasticity in Nrf2-deficient cancer cell lines. Oncogene 29:3703-14
Smith, J Joshua; Deane, Natasha G; Wu, Fei et al. (2010) Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 138:958-68
Krishnan, M; Singh, A B; Smith, J J et al. (2010) HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. Oncogene 29:305-12
Nam, Ki Taek; Lee, Hyuk-Joon; Smith, J Joshua et al. (2010) Loss of Rab25 promotes the development of intestinal neoplasia in mice and is associated with human colorectal adenocarcinomas. J Clin Invest 120:840-9

Showing the most recent 10 out of 48 publications